



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: August 28, 2009

To: NCCTG Primary Clinical Research Associates

From: Alicia Elsing
Research Protocol Specialist

Re: N0321, Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)

The Eligibility Checklist has been revised as follows:

Form Title	Brief Description of Edit
Eligibility Checklist	<p>Addendum 11, dated February 20, 2009 required IRB approval prior to enrollment, all sites should have submitted Addendum 11 through their IRB, and therefore, the following has been removed from page 1 of 4:</p> <ul style="list-style-type: none">• Addendum 11 dated February 20, 2009 IRB approved? ___ Yes. If Yes, Addendum 11 approval date (<i>mm/dd/yyyy</i>) ___ ___/___ ___/___ ___ ___ ___ No. If No, End form, Addendum 11 IRB approval required.

If you have any questions, please feel free to contact me at 507/284-4852.

AE/dg
Enclosure